Published in Carcinogenesis on July 20, 2012
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 1.24
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle (2013) 1.23
Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol (2015) 1.22
Mutant p53: One, No One, and One Hundred Thousand. Front Oncol (2015) 1.02
SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Oncotarget (2014) 0.97
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med (2013) 0.97
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev (2015) 0.96
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res (2014) 0.94
MDM2 promotes invasion and metastasis in invasive ductal breast carcinoma by inducing matrix metalloproteinase-9. PLoS One (2013) 0.91
The family that eats together stays together: new p53 family transcriptional targets in autophagy. Genes Dev (2013) 0.89
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. BMC Cancer (2013) 0.88
miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ (2013) 0.88
Personalized biochemistry and biophysics. Biochemistry (2015) 0.88
MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene (2015) 0.87
AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014) 0.87
Integrative network-based approach identifies key genetic elements in breast invasive carcinoma. BMC Genomics (2015) 0.85
Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure. PLoS One (2014) 0.84
Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. Biosci Rep (2013) 0.84
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget (2016) 0.82
Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis (2015) 0.81
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. BMC Cancer (2014) 0.81
YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep (2015) 0.81
Mutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells. Korean J Physiol Pharmacol (2013) 0.79
Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Oncotarget (2015) 0.79
p53 is active in murine stem cells and alters the transcriptome in a manner that is reminiscent of mutant p53. Cell Death Dis (2015) 0.78
A functional p53 responsive polymorphism in KITLG, rs4590952, does not affect the risk of breast cancer. Sci Rep (2014) 0.78
Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration. PLoS One (2015) 0.77
Genetically engineered ERα-positive breast cancer mouse models. Endocr Relat Cancer (2014) 0.77
Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. Cell Stress Chaperones (2015) 0.77
Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. Pharmacogenomics J (2015) 0.77
Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer. Oncotarget (2016) 0.77
The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells. Mol Cell Biochem (2015) 0.77
Extraction of Molecular Features through Exome to Transcriptome Alignment. J Metabolomics Syst Biol (2013) 0.76
Molecular heterogeneity in adjacent cells in triple-negative breast cancer. Breast Cancer (Dove Med Press) (2015) 0.76
Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. Int J Environ Res Public Health (2015) 0.76
Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model. PLoS One (2015) 0.76
A Physical Mechanism and Global Quantification of Breast Cancer. PLoS One (2016) 0.76
Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells. Oncotarget (2015) 0.75
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun (2016) 0.75
Association of multiple genetic variants with breast cancer susceptibility in the Han Chinese population. Oncotarget (2016) 0.75
Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast Cancer Res Treat (2017) 0.75
Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas. Appl Immunohistochem Mol Morphol (2016) 0.75
PIN1 in breast development and cancer: a clinical perspective. Cell Death Differ (2016) 0.75
The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy. Br J Cancer (2016) 0.75
Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. Oncotarget (2016) 0.75
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis (2016) 0.75
TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. Sci Rep (2015) 0.75
RNF38 encodes a nuclear ubiquitin protein ligase that modifies p53. Biochem Biophys Res Commun (2013) 0.75
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant. PLoS One (2017) 0.75
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer (2017) 0.75
Molecular biology of gynecological cancer. Oncol Lett (2015) 0.75
Adenovirus replaces mitotic checkpoint controls. J Virol (2015) 0.75
p53 siRNA - a therapeutic tool with significant implication in the modulation of apoptosis and angiogenic pathways. Clujul Med (2015) 0.75
Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death Dis (2017) 0.75
High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients. PLoS One (2015) 0.75
MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death Dis (2017) 0.75
The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Rep (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Modulation of microRNA processing by p53. Nature (2009) 7.88
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
p53 status and the efficacy of cancer therapy in vivo. Science (1994) 6.72
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell (2009) 6.64
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell (2010) 5.57
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med (1996) 4.51
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Gain of function mutations in p53. Nat Genet (1993) 4.19
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 4.10
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A (2003) 4.06
Pharmacological rescue of mutant p53 conformation and function. Science (1999) 3.91
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 3.86
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 3.69
Coping with stress: multiple ways to activate p53. Oncogene (2007) 3.57
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell (1984) 3.05
MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets (2005) 3.04
High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science (1994) 2.98
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol (2011) 2.94
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J (2000) 2.73
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol (2001) 2.69
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene (2000) 2.65
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle (2011) 2.46
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol (1999) 2.41
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30
Inflammatory breast cancer: what progress have we made? Oncology (Williston Park) (2011) 2.25
Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 2.20
Minireview: IGF, Insulin, and Cancer. Endocrinology (2011) 2.16
p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol (2010) 2.16
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A (1996) 2.09
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle (2008) 2.03
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene (1994) 2.01
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene (2006) 2.01
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 1.95
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ (2011) 1.94
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A (2010) 1.78
Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 1.77
Li-fraumeni syndrome. Genes Cancer (2011) 1.77
Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res (2011) 1.77
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ (2011) 1.76
High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A (2000) 1.73
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res (2011) 1.71
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res (2001) 1.69
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med (1997) 1.68
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci U S A (2001) 1.65
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res (2009) 1.61
Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med (2010) 1.60
Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res (2004) 1.59
A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A (2002) 1.58
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene (2010) 1.54
Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res (2010) 1.52
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest (2012) 1.49
p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ (2010) 1.47
Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem (2006) 1.44
Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem (2000) 1.43
Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res (2007) 1.42
Links between mutant p53 and genomic instability. J Cell Biochem (2012) 1.41
Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol (2004) 1.39
The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol (2009) 1.39
p53 Isoforms: An Intracellular Microprocessor? Genes Cancer (2011) 1.37
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A (2008) 1.36
How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol (2004) 1.35
The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer (2008) 1.35
Mutant p53 mediates survival of breast cancer cells. Br J Cancer (2009) 1.33
Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science (2007) 3.92
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature (2012) 3.08
The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature (2002) 3.02
Intragenic enhancers act as alternative promoters. Mol Cell (2012) 2.85
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol (2005) 2.13
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol (2010) 1.76
Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell (2004) 1.55
Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Mol Biol Cell (2004) 1.51
The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol (2009) 1.44
Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol (2003) 1.32
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle (2013) 1.23
Modification of the erythroid transcription factor GATA-1 by SUMO-1. Proc Natl Acad Sci U S A (2004) 1.21
Post-phosphorylation prolyl isomerisation of gephyrin represents a mechanism to modulate glycine receptors function. EMBO J (2007) 1.20
Prolyl isomerase PIN1 regulates DNA double-strand break repair by counteracting DNA end resection. Mol Cell (2013) 1.19
hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem (2004) 1.18
The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function. J Biol Chem (2003) 1.18
HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res (2006) 1.16
The transcriptional repressor hDaxx potentiates p53-dependent apoptosis. J Biol Chem (2004) 1.16
Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. Nat Med (2010) 1.14
Pin1 and WWP2 regulate GluR2 Q/R site RNA editing by ADAR2 with opposing effects. EMBO J (2011) 1.13
A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network. Proc Natl Acad Sci U S A (2010) 1.11
Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J Biol Chem (2009) 1.10
Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol (2005) 1.05
The prolyl isomerase Pin1 affects Che-1 stability in response to apoptotic DNA damage. J Biol Chem (2007) 0.98
Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha. Cancer Res (2009) 0.98
Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proc Natl Acad Sci U S A (2011) 0.97
Modification of Drosophila p53 by SUMO modulates its transactivation and pro-apoptotic functions. J Biol Chem (2008) 0.97
Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. Eur J Biochem (2003) 0.97
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med (2013) 0.97
Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. J Biol Chem (2010) 0.95
Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med (2013) 0.94
p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 0.90
Gene regulation and tumor suppression by the bromodomain-containing protein BRD7. Cell Cycle (2010) 0.90
Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget (2011) 0.89
Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res (2008) 0.88
Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6. PLoS One (2012) 0.87
Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol (2003) 0.86
Proline isomerase Pin1 represses terminal differentiation and myocyte enhancer factor 2C function in skeletal muscle cells. J Biol Chem (2010) 0.85
p53-mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y. Int J Biochem Cell Biol (2008) 0.84
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood (2007) 0.83
CEP89 is required for mitochondrial metabolism and neuronal function in man and fly. Hum Mol Genet (2013) 0.82
KeePin' the p53 family in good shape. Cell Cycle (2004) 0.80
Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target. Oncogene (2003) 0.80
Cooperation of p53 mutations with other oncogenic alterations in cancer. Subcell Biochem (2014) 0.78
The evolutionary conserved gene C16orf35 encodes a nucleo-cytoplasmic protein that interacts with p73. Biochem Biophys Res Commun (2009) 0.78
p53 orchestrates calcium signaling in vivo. Cell Cycle (2015) 0.76
Polo-like kinase 2: a new exploitable target to undermine mutant p53-dependent chemoresistance. Cell Cycle (2012) 0.76
Improving pharmacological rescue of p53 function: RITA targets mutant p53. Cell Cycle (2010) 0.75
Leaching of Glyphosate and Aminomethylphosphonic Acid through Silty Clay Soil Columns under Outdoor Conditions. J Environ Qual (2015) 0.75
HIV-1 integrase binding to its cellular partners: a perspective from computational biology. Curr Pharm Des (2014) 0.75
Urban Soil: Assessing Ground Cover Impact on Surface Temperature and Thermal Comfort. J Environ Qual (2016) 0.75
Modeling Tree Shade Effect on Urban Ground Surface Temperature. J Environ Qual (2016) 0.75
Transport of Glyphosate and Aminomethylphosphonic Acid under Two Soil Management Practices in an Italian Vineyard. J Environ Qual (2016) 0.75